Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
20
DCGO Quote, Financials, Valuation and Earnings
Last price:
$0.88
Seasonality move
:
-2.49%
Day range:
$0.88 - $0.92
52-week range:
$0.86 - $5.68
Dividend yield:
0%
P/E ratio:
8.24x
P/S ratio:
0.24x
P/B ratio:
0.32x
Volume:
473.6K
Avg. volume:
724.4K
1-year change:
-79.76%
Market cap:
$86.7M
Revenue:
$616.6M
EPS (TTM):
-$0.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DCGO
DocGo, Inc.
|
$69.2M | -$0.11 | -41.94% | -191.36% | $2.75 |
|
AMS
American Shared Hospital Services
|
$7.5M | -- | -3.19% | -100% | $4.50 |
|
ASTH
Astrana Health, Inc.
|
$952.8M | $0.61 | 39.88% | 82.8% | $37.6667 |
|
CCEL
Cryo-Cell International, Inc.
|
$7.7M | -$0.09 | -4.04% | -60.92% | $8.50 |
|
PIII
P3 Health Partners, Inc.
|
$346.6M | -$0.09 | -3.52% | -- | $10.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DCGO
DocGo, Inc.
|
$0.89 | $2.75 | $86.7M | 8.24x | $0.00 | 0% | 0.24x |
|
AMS
American Shared Hospital Services
|
$2.12 | $4.50 | $13.9M | 11.73x | $0.00 | 0% | 0.47x |
|
ASTH
Astrana Health, Inc.
|
$25.1800 | $37.6667 | $1.3B | 132.53x | $0.00 | 0% | 0.43x |
|
CCEL
Cryo-Cell International, Inc.
|
$3.49 | $8.50 | $28.1M | 498.00x | $0.15 | 18.63% | 0.89x |
|
PIII
P3 Health Partners, Inc.
|
$3.53 | $10.25 | $11.5M | -- | $0.00 | 0% | 0.01x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DCGO
DocGo, Inc.
|
9.82% | 0.493 | 23.92% | 2.53x |
|
AMS
American Shared Hospital Services
|
50.05% | 0.126 | 110.57% | 1.02x |
|
ASTH
Astrana Health, Inc.
|
58.37% | -0.163 | 92.2% | 1.34x |
|
CCEL
Cryo-Cell International, Inc.
|
-564.01% | 1.723 | 33.28% | 0.78x |
|
PIII
P3 Health Partners, Inc.
|
107.59% | -0.008 | 396.37% | 0.28x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DCGO
DocGo, Inc.
|
$14.2M | -$25.2M | -17.57% | -20.69% | -35.64% | $101.1K |
|
AMS
American Shared Hospital Services
|
$1.6M | $48K | -6.67% | -12.09% | 0.67% | -$2M |
|
ASTH
Astrana Health, Inc.
|
$81.6M | $19.2M | 0.88% | 1.85% | 2.01% | $7.4M |
|
CCEL
Cryo-Cell International, Inc.
|
$5.8M | $1.9M | -20.01% | -- | 24.29% | $2.5M |
|
PIII
P3 Health Partners, Inc.
|
-$45.6M | -$44.2M | -89.85% | -223.63% | -12.81% | -$15.5M |
DocGo, Inc. vs. Competitors
-
Which has Higher Returns DCGO or AMS?
American Shared Hospital Services has a net margin of -41.88% compared to DocGo, Inc.'s net margin of -4.59%. DocGo, Inc.'s return on equity of -20.69% beat American Shared Hospital Services's return on equity of -12.09%.
Company Gross Margin Earnings Per Share Invested Capital DCGODocGo, Inc.19.99% -$0.28 $290.1M AMSAmerican Shared Hospital Services21.94% -$0.00 $53.2M -
What do Analysts Say About DCGO or AMS?
DocGo, Inc. has a consensus price target of $2.75, signalling upside risk potential of 210.24%. On the other hand American Shared Hospital Services has an analysts' consensus of $4.50 which suggests that it could grow by 112.26%. Given that DocGo, Inc. has higher upside potential than American Shared Hospital Services, analysts believe DocGo, Inc. is more attractive than American Shared Hospital Services.
Company Buy Ratings Hold Ratings Sell Ratings DCGODocGo, Inc.3 3 0 AMSAmerican Shared Hospital Services0 0 0 -
Is DCGO or AMS More Risky?
DocGo, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison American Shared Hospital Services has a beta of 0.122, suggesting its less volatile than the S&P 500 by 87.793%.
-
Which is a Better Dividend Stock DCGO or AMS?
DocGo, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. American Shared Hospital Services offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocGo, Inc. pays -- of its earnings as a dividend. American Shared Hospital Services pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DCGO or AMS?
DocGo, Inc. quarterly revenues are $70.8M, which are larger than American Shared Hospital Services quarterly revenues of $7.2M. DocGo, Inc.'s net income of -$29.7M is lower than American Shared Hospital Services's net income of -$329K. Notably, DocGo, Inc.'s price-to-earnings ratio is 8.24x while American Shared Hospital Services's PE ratio is 11.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo, Inc. is 0.24x versus 0.47x for American Shared Hospital Services. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DCGODocGo, Inc.0.24x 8.24x $70.8M -$29.7M AMSAmerican Shared Hospital Services0.47x 11.73x $7.2M -$329K
-
Which has Higher Returns DCGO or ASTH?
Astrana Health, Inc. has a net margin of -41.88% compared to DocGo, Inc.'s net margin of 0.11%. DocGo, Inc.'s return on equity of -20.69% beat Astrana Health, Inc.'s return on equity of 1.85%.
Company Gross Margin Earnings Per Share Invested Capital DCGODocGo, Inc.19.99% -$0.28 $290.1M ASTHAstrana Health, Inc.8.54% $0.01 $1.6B -
What do Analysts Say About DCGO or ASTH?
DocGo, Inc. has a consensus price target of $2.75, signalling upside risk potential of 210.24%. On the other hand Astrana Health, Inc. has an analysts' consensus of $37.6667 which suggests that it could grow by 49.59%. Given that DocGo, Inc. has higher upside potential than Astrana Health, Inc., analysts believe DocGo, Inc. is more attractive than Astrana Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DCGODocGo, Inc.3 3 0 ASTHAstrana Health, Inc.8 2 0 -
Is DCGO or ASTH More Risky?
DocGo, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.862, suggesting its less volatile than the S&P 500 by 13.753%.
-
Which is a Better Dividend Stock DCGO or ASTH?
DocGo, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocGo, Inc. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DCGO or ASTH?
DocGo, Inc. quarterly revenues are $70.8M, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. DocGo, Inc.'s net income of -$29.7M is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, DocGo, Inc.'s price-to-earnings ratio is 8.24x while Astrana Health, Inc.'s PE ratio is 132.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo, Inc. is 0.24x versus 0.43x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DCGODocGo, Inc.0.24x 8.24x $70.8M -$29.7M ASTHAstrana Health, Inc.0.43x 132.53x $956M $1.1M
-
Which has Higher Returns DCGO or CCEL?
Cryo-Cell International, Inc. has a net margin of -41.88% compared to DocGo, Inc.'s net margin of 9.58%. DocGo, Inc.'s return on equity of -20.69% beat Cryo-Cell International, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DCGODocGo, Inc.19.99% -$0.28 $290.1M CCELCryo-Cell International, Inc.74.61% $0.09 -$2.2M -
What do Analysts Say About DCGO or CCEL?
DocGo, Inc. has a consensus price target of $2.75, signalling upside risk potential of 210.24%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 143.55%. Given that DocGo, Inc. has higher upside potential than Cryo-Cell International, Inc., analysts believe DocGo, Inc. is more attractive than Cryo-Cell International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DCGODocGo, Inc.3 3 0 CCELCryo-Cell International, Inc.0 1 0 -
Is DCGO or CCEL More Risky?
DocGo, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.669, suggesting its less volatile than the S&P 500 by 33.089%.
-
Which is a Better Dividend Stock DCGO or CCEL?
DocGo, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 18.63% to investors and pays a quarterly dividend of $0.15 per share. DocGo, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.
-
Which has Better Financial Ratios DCGO or CCEL?
DocGo, Inc. quarterly revenues are $70.8M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. DocGo, Inc.'s net income of -$29.7M is lower than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, DocGo, Inc.'s price-to-earnings ratio is 8.24x while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo, Inc. is 0.24x versus 0.89x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DCGODocGo, Inc.0.24x 8.24x $70.8M -$29.7M CCELCryo-Cell International, Inc.0.89x 498.00x $7.8M $749.4K
-
Which has Higher Returns DCGO or PIII?
P3 Health Partners, Inc. has a net margin of -41.88% compared to DocGo, Inc.'s net margin of -20.12%. DocGo, Inc.'s return on equity of -20.69% beat P3 Health Partners, Inc.'s return on equity of -223.63%.
Company Gross Margin Earnings Per Share Invested Capital DCGODocGo, Inc.19.99% -$0.28 $290.1M PIIIP3 Health Partners, Inc.-13.2% -$9.67 $283.9M -
What do Analysts Say About DCGO or PIII?
DocGo, Inc. has a consensus price target of $2.75, signalling upside risk potential of 210.24%. On the other hand P3 Health Partners, Inc. has an analysts' consensus of $10.25 which suggests that it could grow by 190.37%. Given that DocGo, Inc. has higher upside potential than P3 Health Partners, Inc., analysts believe DocGo, Inc. is more attractive than P3 Health Partners, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DCGODocGo, Inc.3 3 0 PIIIP3 Health Partners, Inc.1 1 0 -
Is DCGO or PIII More Risky?
DocGo, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison P3 Health Partners, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock DCGO or PIII?
DocGo, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DocGo, Inc. pays -- of its earnings as a dividend. P3 Health Partners, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DCGO or PIII?
DocGo, Inc. quarterly revenues are $70.8M, which are smaller than P3 Health Partners, Inc. quarterly revenues of $345.3M. DocGo, Inc.'s net income of -$29.7M is higher than P3 Health Partners, Inc.'s net income of -$69.5M. Notably, DocGo, Inc.'s price-to-earnings ratio is 8.24x while P3 Health Partners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DocGo, Inc. is 0.24x versus 0.01x for P3 Health Partners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DCGODocGo, Inc.0.24x 8.24x $70.8M -$29.7M PIIIP3 Health Partners, Inc.0.01x -- $345.3M -$69.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
